[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 607
46. Al-Anazi AH, Al-Luwimi IM, Shawarby MA, Mertol T: Mixed vestibular schwannoma and meningioma without neurofibromatosis. Neurosciences (Riyadh); 2009 Oct;14(4):371-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed vestibular schwannoma and meningioma without neurofibromatosis.
  • The co-existence of meningioma and schwannoma as 2 distinct histologic components within the same tumor has been described in neurofibromatosis 2 (NF2), but the co-existence of both tumors without evidence of NF2 is much rarer.
  • Here, we are reporting a case of mixed schwannoma with meningioma without clinical evidence of NF2.
  • In an adult Saudi lady with progressive left-sided hearing loss, left cerebellopontine tumor was diagnosed by MRI, and the histopathological diagnosis revealed that this tumor was composed of vestibular schwannoma and meningioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21048654.001).
  • [ISSN] 1319-6138
  • [Journal-full-title] Neurosciences (Riyadh, Saudi Arabia)
  • [ISO-abbreviation] Neurosciences (Riyadh)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


47. Ng YS, Lyons CJ: Oculomotor nerve palsy in childhood. Can J Ophthalmol; 2005 Oct;40(5):645-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The management of children with oculomotor nerve palsy is complicated by their variable presentation, amblyopia, potential loss of binocularity, and associated neurological disease.
  • Primary aberrant regeneration was the presenting sign in a child with neurofibromatosis type 2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16391633.001).
  • [ISSN] 0008-4182
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


48. Massager N, Nissim O, Delbrouck C, Devriendt D, David P, Desmedt F, Wikler D, Hassid S, Brotchi J, Levivier M: Role of intracanalicular volumetric and dosimetric parameters on hearing preservation after vestibular schwannoma radiosurgery. Int J Radiat Oncol Biol Phys; 2006 Apr 1;64(5):1331-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of intracanalicular volumetric and dosimetric parameters on hearing preservation after vestibular schwannoma radiosurgery.
  • PURPOSE: To analyze the relationship between hearing preservation after gamma knife radiosurgery (GKR) for vestibular schwannoma (VS) and some volumetric and dosimetric parameters of the intracanalicular components of vs. METHODS AND MATERIALS: This study included 82 patients with a VS treated by GKR; all patients had no NF2 disease, a Gardner-Robertson hearing class 1-4 before treatment, a marginal dose of 12 Gy, and a radiologic and audiologic follow-up > or =1 year post-GKR.
  • [MeSH-major] Neuroma, Acoustic / surgery. Radiosurgery

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16458446.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Guntinas-Lichius O: Hearing improvement after bevacizumab for neurofibromatosis type 2. N Engl J Med; 2009 Oct 29;361(18):1809-10; author reply 1810-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hearing improvement after bevacizumab for neurofibromatosis type 2.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Hearing Loss / drug therapy. Neurofibromatosis 2 / complications. Neuroma, Acoustic / drug therapy

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] N Engl J Med. 2009 Jul 23;361(4):358-67 [19587327.001]
  • (PMID = 19864683.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


50. Jaurand MC, Fleury-Feith J: Pathogenesis of malignant pleural mesothelioma. Respirology; 2005 Jan;10(1):2-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Genetic alterations in the tumour suppressor genes, P16/CDKN2A and neurofibromatosis 2 (NF2), are found both in human MPM and in asbestos-exposed Nf2-deficient mice.
  • Despite a ban on asbestos use in Western countries, the incidence of MPM is increasing, due to the long delay between asbestos exposure and diagnosis.
  • [MeSH-minor] Animals. Asbestosis / complications. Cell Transformation, Neoplastic / pathology. Cocarcinogenesis. Genes, Neurofibromatosis 2. Genes, Tumor Suppressor. Humans. Mice. Polyomavirus Infections / complications. Simian virus 40. Tumor Virus Infections / complications


51. Retrosi G, Nanni L, Ricci R, Manzoni C, Pintus C: Plexiform schwannoma of the esophagus in a child with neurofibromatosis type 2. J Pediatr Surg; 2009 Jul;44(7):1458-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plexiform schwannoma of the esophagus in a child with neurofibromatosis type 2.
  • Schwannoma is a benign neoplasia of the peripheral nerve sheath.
  • According to the existing literature esophageal schwannoma has been reported so far only in adult patients.
  • We report the case of an 11 year old patient with neurofibromatosis, type 2, who underwent surgical excision of a plexiform schwannoma of the esophagus.
  • [MeSH-major] Esophageal Neoplasms / diagnosis. Esophagectomy / methods. Neoplasms, Multiple Primary. Neurilemmoma / diagnosis. Neurofibromatosis 2 / diagnosis
  • [MeSH-minor] Child. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed


52. Jatana KR, Jacob A, Slone HW, Ray-Chaudhury A, Welling DB: Spinal myxopapillary ependymoma metastatic to bilateral internal auditory canals. Ann Otol Rhinol Laryngol; 2008 Feb;117(2):98-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal myxopapillary ependymoma metastatic to bilateral internal auditory canals.
  • OBJECTIVES: We report a rare case of spinal myxopapillary ependymoma metastatic to both internal auditory canals (IACs) and its implications for diagnosing neurofibromatosis type 2 (NF2).
  • METHODS: We present a detailed clinical history, magnetic resonance imaging (MRI), intraoperative photographs, and histopathologic findings from a patient with bilateral IAC lesions, and review the diagnostic criteria for NF2.
  • The diagnosis of NF2 with bilateral vestibular schwannomas was entertained.
  • This finding raised the possibility of other, more unusual IAC lesions.
  • The patient underwent sequential suboccipital craniotomies for tissue diagnosis, and both IAC lesions were found to be myxopapillary ependymomas.
  • Although vestibular schwannomas account for the majority of contrast-enhancing T1-weighted IAC lesions, other uncommon lesions may present in a similar manner.
  • Therefore, both T1-weighted MRI with or without contrast and T2-weighted MRI may be necessary to distinguish vestibular schwannoma from other, more unusual IAC lesions.
  • [MeSH-major] Ear Neoplasms / diagnosis. Ear Neoplasms / secondary. Ependymoma / diagnosis. Ependymoma / secondary. Labyrinth Diseases / diagnosis. Spinal Cord Neoplasms / pathology

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Myxopapillary ependymoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357830.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Soos S, Balasko M, Jech-Mihalffy A, Szekely M, Petervari E: Anorexic vs. metabolic effects of central leptin infusion in rats of various ages and nutritional states. J Mol Neurosci; 2010 May;41(1):97-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anorexic vs. metabolic effects of central leptin infusion in rats of various ages and nutritional states.
  • In the present experiments, the anorexic (suppressing food intake and body weight) and hypermetabolic (increasing body temperature (Tc), activity, and heart rate (HR), indicating metabolic rate) responses to 7-day-long intracerebroventricular leptin infusion were compared in 2- and 6-month-old normally fed (NF2 and NF6 groups), 6-month-old high-fat-diet-induced obese (HF6), and 6-month-old calorie-restricted (CR6) rats.
  • The anorexic effects were inversely related to fat content: They were most pronounced in NF2, less in NF6, non-significant in HF6 rats, but also absent in CR6 animals of the lowest fat content.
  • In contrast, CR6 rats were hypersensitive to the metabolic effects of leptin infusion (rise in Tc and HR; biotelemetric measurements), NF2 were still sensitive, while NF6 and HF6 rats exhibited moderate or low sensitivity.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol. 1999 May;276(5 Pt 2):R1425-33 [10233036.001]
  • [Cites] Pflugers Arch. 1978 Feb 22;373(2):189-93 [565045.001]
  • [Cites] Endocrinology. 2008 Mar;149(3):1121-8 [18048492.001]
  • [Cites] FASEB J. 2004 Dec;18(15):1949-51 [15388670.001]
  • [Cites] Physiol Behav. 2002 Sep;77(1):65-77 [12213503.001]
  • [Cites] Neuropeptides. 2005 Apr;39(2):103-15 [15752544.001]
  • [Cites] J Neuroendocrinol. 2002 Nov;14(11):887-93 [12421342.001]
  • [Cites] Neuropharmacology. 2000 Jul 24;39(10):1872-9 [10884568.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2001 Oct;56 Spec No 2:81-8 [11730241.001]
  • [Cites] Endocrinology. 1999 Sep;140(9):4015-23 [10465271.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2002 Oct;283(4):R941-8 [12228064.001]
  • [Cites] Endocrinology. 2004 Nov;145(11):4880-9 [15271881.001]
  • [Cites] Endocrinology. 2004 Jun;145(6):2613-20 [15044360.001]
  • [Cites] J Pharmacol Toxicol Methods. 2007 Sep-Oct;56(2):218-22 [17596971.001]
  • [Cites] Neuroendocrinology. 2005;82(5-6):256-63 [16721031.001]
  • [Cites] Diabetes. 2000 Mar;49(3):431-5 [10868965.001]
  • [Cites] Dig Dis. 2007;25(2):129-37 [17468548.001]
  • [Cites] J Clin Invest. 2000 Jun;105(12):1827-32 [10862798.001]
  • [Cites] Nature. 1998 Oct 22;395(6704):763-70 [9796811.001]
  • [Cites] J Biol Chem. 2006 Jul 14;281(28):18933-41 [16687413.001]
  • [Cites] Int J Obes Relat Metab Disord. 2000 May;24(5):639-46 [10849588.001]
  • [Cites] Diabetes. 2002 Apr;51(4):1016-21 [11916920.001]
  • (PMID = 19777381.001).
  • [ISSN] 1559-1166
  • [Journal-full-title] Journal of molecular neuroscience : MN
  • [ISO-abbreviation] J. Mol. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Leptin
  •  go-up   go-down


5
Advertisement
4. O'Brien DF, Farrell M, Pidgeon CN: Combined nasal and skull base pathology: adjacent nasal schwannoma and olfactory groove meningioma. Br J Neurosurg; 2005 Oct;19(5):446-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined nasal and skull base pathology: adjacent nasal schwannoma and olfactory groove meningioma.
  • Following surgical removal of the lesion histopathology confirmed the presence of both a nasal schwannoma and an olfactory groove meningioma.
  • This dual pathology may represent a variation of neurofibromatosis type 2 (NF-2).
  • [MeSH-major] Meningioma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Neurilemmoma / diagnosis. Nose Neoplasms / diagnosis. Skull Base Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16455571.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


55. Kameswaran M, Vasudevan MC, Kumar RS, Nagasundaram J, Natarajan K, Raghunandhan S: Auditory brainstem implantation: The first Indian experience. Indian J Otolaryngol Head Neck Surg; 2005 Jan;57(1):58-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multichannel auditory brainstem implants (ABI) are currently indicated for patients with neurofibromatosis type II (NF2) involving both vestibulocochlear nerves.
  • The implant is usually placed in the lateral recess of the fourth ventricle at the time of tumor resection to stimulate the cochlear nucleus.
  • We report a case of ABI done on a 15-year-old girl with bilateral vestibular schwannomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Laryngol Otol Suppl. 2000;(27):11-4 [11211429.001]
  • [Cites] J Laryngol Otol Suppl. 2000;(27):23-6 [11211432.001]
  • [Cites] J Laryngol Otol Suppl. 2000;(27):3-7 [11211434.001]
  • [Cites] Otol Neurotol. 2004 Jul;25(4):485-96; discussion 496 [15241227.001]
  • [Cites] Otol Neurotol. 2003 Jan;24(1):79-82 [12544033.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 May;130(5):656-9 [15148193.001]
  • [Cites] Laryngoscope. 2004 Dec;114(12):2135-46 [15564834.001]
  • [Cites] J Laryngol Otol Suppl. 2000;(27):8-10 [11211442.001]
  • (PMID = 23120129.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3451539
  • [Keywords] NOTNLM ; auditory brainsterm unplants / neurofibromatosis
  •  go-up   go-down


56. Chow HY, Stepanova D, Koch J, Chernoff J: p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. PLoS One; 2010 Nov 02;5(11):e13791
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.
  • BACKGROUND: NF2 is an autosomal dominant disease characterized by development of bilateral vestibular schwannomas and other benign tumors in central nervous system.
  • Loss of the NF2 gene product, Merlin, leads to aberrant Schwann cell proliferation, motility, and survival, but the mechanisms by which this tumor suppressor functions remain unclear.
  • CONCLUSIONS/SIGNIFICANCE: These results suggest that Pak functions in novel signaling pathways in NF2, and may serve as a useful therapeutic target in this disease.

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2000 Mar;66(3):873-91 [10712203.001]
  • [Cites] J Med Genet. 2000 Dec;37(12):897-904 [11106352.001]
  • [Cites] Trends Mol Med. 2001 Apr;7(4):157-62 [11286939.001]
  • [Cites] Dev Cell. 2001 Jul;1(1):63-72 [11703924.001]
  • [Cites] J Biol Chem. 2002 Jan 11;277(2):883-6 [11719502.001]
  • [Cites] Mol Cell Biol. 2002 Feb;22(4):1150-7 [11809806.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10332-6 [11756419.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10394-9 [11782491.001]
  • [Cites] Circ Res. 2002 Apr 5;90(6):697-702 [11934838.001]
  • [Cites] Mol Cell Biol. 2002 Sep;22(17):6023-33 [12167697.001]
  • [Cites] Oncogene. 2002 Sep 5;21(39):5990-7 [12203111.001]
  • [Cites] J Cell Biol. 2003 Jul 21;162(2):281-91 [12876277.001]
  • [Cites] Annu Rev Biochem. 2003;72:743-81 [12676796.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):841-9 [14580336.001]
  • [Cites] J Cell Sci. 2004 Sep 1;117(Pt 19):4343-54 [15331659.001]
  • [Cites] Mol Cell Biol. 1997 Aug;17(8):4454-64 [9234703.001]
  • [Cites] Oncogene. 1997 Nov 13;15(20):2505-9 [9395247.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5139-44 [9560242.001]
  • [Cites] J Cell Biol. 1998 Jun 29;141(7):1589-99 [9647651.001]
  • [Cites] EMBO J. 1998 Aug 3;17(15):4328-39 [9687501.001]
  • [Cites] Oncogene. 1998 Oct 29;17(17):2195-209 [9811451.001]
  • [Cites] Nature. 1998 Nov 12;396(6707):180-3 [9823899.001]
  • [Cites] J Cell Biol. 2005 Oct 24;171(2):361-71 [16247032.001]
  • [Cites] Mol Cell. 2005 Oct 28;20(2):237-49 [16246726.001]
  • [Cites] J Biol Chem. 2005 Nov 4;280(44):36609-15 [16129686.001]
  • [Cites] Nat Neurosci. 2006 Feb;9(2):234-42 [16415866.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4463-8 [16537381.001]
  • [Cites] Nature. 2006 Aug 3;442(7102):576-9 [16885985.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):520-7 [17234759.001]
  • [Cites] Cell Motil Cytoskeleton. 2007 Mar;64(3):143-56 [17183546.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3261-6 [17360635.001]
  • [Cites] Biol Cell. 2008 Feb;100(2):97-108 [18199048.001]
  • [Cites] J Cell Sci. 2008 Apr 1;121(Pt 7):933-8 [18319303.001]
  • [Cites] Chem Biol. 2008 Apr;15(4):322-31 [18420139.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):5236-45 [18593924.001]
  • [Cites] Oncogene. 2008 Aug 21;27(36):4900-8 [18427546.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7932-7 [18829550.001]
  • [Cites] J Am Chem Soc. 2008 Nov 26;130(47):15764-5 [18973295.001]
  • [Cites] Cancer Metastasis Rev. 2009 Jun;28(1-2):51-63 [19165420.001]
  • [Cites] Exp Neurol. 2009 Jul;218(1):137-44 [19409384.001]
  • [Cites] J Cell Biochem. 2009 Jul 1;107(4):579-85 [19350548.001]
  • [Cites] Mol Cell Biol. 2009 Aug;29(15):4250-61 [19451225.001]
  • [Cites] Mol Cell Biol. 2009 Aug;29(15):4235-49 [19451229.001]
  • [Cites] Mol Cell. 2010 Apr 23;38(2):236-49 [20417602.001]
  • (PMID = 21072183.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006927; United States / NCI NIH HHS / CA / R01 CA117884; United States / NCI NIH HHS / CA / CA117884
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurofibromin 2; EC 2.7.11.1 / p21-Activated Kinases
  • [Other-IDs] NLM/ PMC2970553
  •  go-up   go-down


57. Łaniewski-Wołłk M, Gos M, Koziarski A, Szpecht-Potocka A: Identification of mutations in the NF2 gene in Polish patients with neurofibromatosis type 2. J Appl Genet; 2008;49(3):297-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of mutations in the NF2 gene in Polish patients with neurofibromatosis type 2.
  • Point mutation and loss of heterozygosity (LOH) analyses were performed in 12 Polish patients with a classic symptom of NF2 - bilateral vestibular schwannomas (BVS).
  • In 5 patients (41.7%), germline mutations were found in the NF2 gene: 2 previously reported substitutions (c.592C>T and c.52C>T) and 3 novel mutations (c.1001_1002insG, c.1029_1030insCC, c.774_778dupGAATG).
  • In addition, LOH analysis of 30 tumour samples from 10 patients revealed a molecular basis of NF2 in 3 patients (25%) that did not have any germline mutation.
  • The molecular defects in sporadic cases of NF2 are still being discussed.
  • [MeSH-major] Germ-Line Mutation / genetics. Loss of Heterozygosity. Neurofibromatosis 2 / genetics

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1996 May;38(5):880-5; discussion 885-6 [8727812.001]
  • [Cites] J Med Genet. 2003 Feb;40(2):109-14 [12566519.001]
  • [Cites] Hum Mol Genet. 1994 Mar;3(3):413-9 [8012353.001]
  • [Cites] J Cell Sci. 2001 May;114(Pt 10):1901-12 [11329377.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] J Biol Chem. 2001 Aug 31;276(35):33093-100 [11432873.001]
  • [Cites] Oncogene. 1997 Nov 13;15(20):2505-9 [9395247.001]
  • [Cites] Neurology. 2002 Dec 10;59(11):1759-65 [12473765.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):442-4 [11684412.001]
  • [Cites] Am J Hum Genet. 1996 Aug;59(2):331-42 [8755919.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • [Cites] Am J Hum Genet. 1996 Sep;59(3):529-39 [8751853.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Apr;42(4):384-91 [15645494.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10332-6 [11756419.001]
  • [Cites] J Pathol. 2006 Mar;208(4):564-73 [16353169.001]
  • [Cites] J Cell Sci. 1999 Mar;112 ( Pt 6):895-904 [10036239.001]
  • [Cites] Hum Genet. 1996 Nov;98(5):534-8 [8882871.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Feb;12(2):117-27 [7535084.001]
  • [Cites] J Med Genet. 1998 Jun;35(6):450-5 [9643284.001]
  • [Cites] Am J Med Genet. 1994 Oct 1;52(4):450-61 [7747758.001]
  • [Cites] Genes Dev. 2001 Apr 15;15(8):968-80 [11316791.001]
  • (PMID = 18670066.001).
  • [ISSN] 1234-1983
  • [Journal-full-title] Journal of applied genetics
  • [ISO-abbreviation] J. Appl. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


58. Nakamura E, Kaelin WG Jr: Recent insights into the molecular pathogenesis of pheochromocytoma and paraganglioma. Endocr Pathol; 2006;17(2):97-106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These tumors can arise in the context of hereditary cancer syndromes such as von Hippel- Lindau disease, multiple endocrine neoplasia type 2, and neurofibromatosis 1.
  • This review focuses on the genetics of these tumors and suggests a possible link between familial pheochromocytomas/paraganglioma genes and control of neuronal apoptosis during embryological development.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Fetal Development / physiology. Genetic Predisposition to Disease. Paraganglioma / genetics. Pheochromocytoma / genetics

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1996 Sep 26;335(13):943-51 [8782503.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Aug;81(8):2881-4 [8768845.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Sep 24;263(2):491-7 [10491320.001]
  • [Cites] Mol Cancer Res. 2004 Feb;2(2):89-95 [14985465.001]
  • [Cites] Genes Dev. 1996 Jun 15;10(12):1455-66 [8666230.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):673-82 [12209156.001]
  • [Cites] Pathology. 2005 Feb;37(1):10-3 [15875728.001]
  • [Cites] Ann Intern Med. 2001 Feb 20;134(4):315-29 [11182843.001]
  • [Cites] N Engl J Med. 1993 Nov 18;329(21):1531-8 [8105382.001]
  • [Cites] J Cell Biol. 1994 Dec;127(6 Pt 1):1717-27 [7798322.001]
  • [Cites] Biochem J. 2004 Aug 1;381(Pt 3):761-7 [15104534.001]
  • [Cites] J Biol Chem. 2003 Dec 5;278(49):48690-5 [14506252.001]
  • [Cites] Science. 1995 Nov 24;270(5240):1326-31 [7481820.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Dec;47(6):707-12 [9497878.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):155-67 [16098468.001]
  • [Cites] N Engl J Med. 1981 Dec 31;305(27):1617-27 [6796886.001]
  • [Cites] Nat Cell Biol. 2002 May;4(5):E131-6 [11988758.001]
  • [Cites] Cell Mol Neurobiol. 1994 Oct;14(5):487-505 [7621509.001]
  • [Cites] J Biol Chem. 1998 Oct 9;273(41):26277-80 [9756852.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):247-55 [12086861.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):859-68 [14668816.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2890-4 [11397905.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Dec;82(12 ):4101-4 [9398721.001]
  • [Cites] J Neurochem. 1999 Jul;73(1):429-32 [10386996.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4568-74 [11134110.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6822-5 [11156372.001]
  • [Cites] J Biol Chem. 2001 Feb 16;276(7):5085-92 [11060309.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 9;338(1):627-38 [16153592.001]
  • [Cites] Hum Mol Genet. 2002 Oct 1;11(20):2347-54 [12351569.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5615-21 [14500403.001]
  • [Cites] Am J Pathol. 2006 Feb;168(2):574-84 [16436671.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):237-46 [12086860.001]
  • [Cites] Neuron. 2002 Jan 17;33(2):261-73 [11804573.001]
  • [Cites] Medicine (Baltimore). 1997 Nov;76(6):381-91 [9413424.001]
  • [Cites] Cell. 1995 Sep 8;82(5):733-42 [7671302.001]
  • [Cites] Lancet. 2001 Apr 14;357(9263):1181-2 [11323050.001]
  • [Cites] JAMA. 1996 Nov 20;276(19):1575-9 [8918855.001]
  • [Cites] Am J Hum Genet. 2001 Jul;69(1):49-54 [11404820.001]
  • [Cites] Nat Genet. 2000 Nov;26(3):268-70 [11062460.001]
  • [Cites] Neuron. 2002 Jan 17;33(2):156-8 [11804563.001]
  • [Cites] PLoS Biol. 2003 Dec;1(3):E83 [14691554.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jul;80(7):2063-8 [7608256.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):77-85 [15652751.001]
  • [Cites] Hum Mol Genet. 2001 May 1;10 (10 ):1019-27 [11331612.001]
  • [Cites] Neuron. 1995 May;14(5):927-39 [7748560.001]
  • [Cites] J Urol. 1999 Sep;162(3 Pt 1):659-64 [10458336.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):857-66 [16327764.001]
  • [Cites] EMBO J. 2003 Aug 15;22(16):4082-90 [12912907.001]
  • [Cites] J Med Genet. 2002 Sep;39(9):617-22 [12205103.001]
  • [Cites] J Biol Chem. 1997 Oct 31;272(44):27509-12 [9346879.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):190-5 [12673678.001]
  • [Cites] Science. 2000 Feb 4;287(5454):848-51 [10657297.001]
  • [Cites] J Cell Biochem. 2004 Jun 1;92 (3):491-501 [15156561.001]
  • [Cites] Medicine (Baltimore). 1991 Jan;70(1):46-66 [1988766.001]
  • [Cites] Hum Mol Genet. 2001 May 1;10 (10 ):1029-38 [11331613.001]
  • [Cites] N Engl J Med. 2002 May 9;346(19):1459-66 [12000816.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Dec;59(6):728-33 [14974914.001]
  • [Cites] J Neurochem. 2003 Apr;85(2):318-28 [12675908.001]
  • [Cites] J Med Genet. 1995 Dec;32(12):934-7 [8825918.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4991-5004 [15611513.001]
  • (PMID = 17159241.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 9061-61-4 / Nerve Growth Factor; EC 1.3.99.1 / Succinate Dehydrogenase
  • [Number-of-references] 63
  •  go-up   go-down


59. Xiao HJ, Au DK, Yau H, Chow CK, Fan YW, Wei WI: Neurofibromatosis type 2 and auditory brainstem implantation. Chin Med J (Engl); 2007 Aug 20;120(16):1456-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis type 2 and auditory brainstem implantation.
  • [MeSH-major] Auditory Brain Stem Implantation / methods. Neurofibromatosis 2 / surgery


60. Baser ME, Rai H, Wallace AJ, Evans DG: Neurofibromatosis 2 (NF2) and malignant mesothelioma in a man with a constitutional NF2 missense mutation. Fam Cancer; 2005;4(4):321-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis 2 (NF2) and malignant mesothelioma in a man with a constitutional NF2 missense mutation.
  • Neurofibromatosis 2 (NF2) is caused by inactivating mutations of the NF2 tumor suppressor gene.
  • Somatic NF2 mutations also occur in a high proportion of human primary malignant mesotheliomas.
  • We report an elderly man with NF2, malignant mesothelioma, and a constitutional NF2 missense mutation.
  • The long latent period for mesothelioma in this patient (61 years) raises the possibility that the type of mutant NF2 allele could affect mesothelioma tumorigenesis or progression.
  • [MeSH-major] Genes, Neurofibromatosis 2. Mesothelioma / complications. Mesothelioma / genetics. Neurofibromatosis 2 / genetics. Occupational Exposure / adverse effects. Pleural Neoplasms / genetics
  • [MeSH-minor] Aged. Asbestos / adverse effects. Humans. Male. Mutation, Missense. Neuroma, Acoustic / etiology. Polymerase Chain Reaction


61. Stamenkovic I, Yu Q: Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr Protein Pept Sci; 2010 Sep;11(6):471-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Genetic alterations of neurofibromatosis type 2 (NF2) gene lead to the development of schwannomas, meningiomas, and ependymomas.
  • Mutations of NF2 gene were also found in thyroid cancer, mesothelioma, and melanoma, suggesting that it functions as a tumor suppressor in a wide spectrum of cells.
  • The product of NF2 gene is merlin (moesin-ezrin-radixin-like protein), a member of the Band 4.1 superfamily proteins.
  • Accumulating data also suggested an emerging role of merlin as a negative regulator of growth and progression of several non-NF2 associated cancer types.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Cell Dev Biol. 2000;16:113-43 [11031232.001]
  • [Cites] J Neurosci Res. 2000 Nov 15;62(4):491-502 [11070492.001]
  • [Cites] EMBO J. 2000 Dec 15;19(24):6778-91 [11118213.001]
  • [Cites] Hum Mol Genet. 1994 Apr;3(4):565-8 [8069299.001]
  • [Cites] J Biol Chem. 1994 Sep 23;269(38):23387-90 [8089100.001]
  • [Cites] Hum Mol Genet. 1994 Jul;3(7):1075-9 [7981675.001]
  • [Cites] Gene. 1995 Dec 29;167(1-2):303-6 [8566796.001]
  • [Cites] Nat Genet. 1998 Apr;18(4):354-9 [9537418.001]
  • [Cites] Genes Dev. 1998 Apr 15;12(8):1121-33 [9553042.001]
  • [Cites] J Cell Biol. 1998 Jun 29;141(7):1589-99 [9647651.001]
  • [Cites] Nat Med. 1998 Aug;4(8):915-22 [9701243.001]
  • [Cites] Biochim Biophys Acta. 1998 Sep 8;1387(1-2):1-16 [9748471.001]
  • [Cites] Oncogene. 1998 Aug 20;17(7):801-10 [9779996.001]
  • [Cites] Oncogene. 1998 Oct 29;17(17):2195-209 [9811451.001]
  • [Cites] J Neurobiol. 1998 Dec;37(4):487-501 [9858254.001]
  • [Cites] Hum Mol Genet. 1999 Feb;8(2):267-75 [9931334.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):177-81 [9988268.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):182-6 [9988269.001]
  • [Cites] J Cell Sci. 1999 Mar;112 ( Pt 6):895-904 [10036239.001]
  • [Cites] Curr Opin Cell Biol. 1999 Feb;11(1):109-16 [10047517.001]
  • [Cites] Hum Mol Genet. 1999 Aug;8(8):1561-70 [10401006.001]
  • [Cites] Oncogene. 1999 Aug 26;18(34):4788-97 [10490812.001]
  • [Cites] Oncogene. 2004 Nov 18;23(54):8815-25 [15467741.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18200-5 [15598747.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1380-5 [15746036.001]
  • [Cites] Cell. 2005 Mar 11;120(5):675-85 [15766530.001]
  • [Cites] Oncogene. 2005 Mar 17;24(12):2076-86 [15688006.001]
  • [Cites] J Biol Chem. 2005 Apr 1;280(13):12517-22 [15699051.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • [Cites] Exp Cell Res. 2005 Aug 1;308(1):177-87 [15913605.001]
  • [Cites] Cell. 2005 Aug 12;122(3):421-34 [16096061.001]
  • [Cites] Oncogene. 2005 Aug 11;24(34):5355-64 [16007223.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 23;335(2):385-92 [16083858.001]
  • [Cites] Science. 2005 Aug 12;309(5737):1074-8 [16099986.001]
  • [Cites] Dev Cell. 2005 Sep;9(3):377-88 [16139226.001]
  • [Cites] Genes Dev. 2005 Oct 1;19(19):2265-77 [16204178.001]
  • [Cites] J Cell Biol. 2005 Oct 24;171(2):361-71 [16247032.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):27-36 [16341207.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Feb 24;340(4):1151-7 [16405865.001]
  • [Cites] Cell. 2006 Jan 27;124(2):267-73 [16439203.001]
  • [Cites] Annu Rev Physiol. 2006;68:491-505 [16460281.001]
  • [Cites] Hum Mol Genet. 2006 Apr 1;15(7):1059-70 [16497727.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1696-708 [16449977.001]
  • [Cites] Curr Biol. 2006 Apr 4;16(7):702-9 [16581517.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Apr;7(4):253-64 [16607288.001]
  • [Cites] Cell. 2006 Jun 30;125(7):1253-67 [16814713.001]
  • [Cites] Semin Pediatr Neurol. 2006 Mar;13(1):21-6 [16818172.001]
  • [Cites] Eur J Cell Biol. 2006 Aug;85(8):769-83 [16762451.001]
  • [Cites] Nature. 2006 Aug 3;442(7102):576-9 [16885985.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12405-10 [16894141.001]
  • [Cites] Oncogene. 2006 Sep 28;25(44):5960-8 [16652148.001]
  • [Cites] Genes Dev. 2006 Oct 1;20(19):2687-700 [17015431.001]
  • [Cites] Nat Med. 2006 Oct;12(10):1175-80 [16998483.001]
  • [Cites] Nat Med. 2006 Oct;12(10):1167-74 [16998484.001]
  • [Cites] Curr Biol. 2006 Nov 7;16(21):2090-100 [16996265.001]
  • [Cites] Curr Biol. 2006 Nov 7;16(21):2081-9 [16996266.001]
  • [Cites] Neurosci Res. 2006 Dec;56(4):450-8 [17049657.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] J Biol Chem. 1998 Mar 27;273(13):7757-64 [9516485.001]
  • [Cites] J Biol Chem. 1999 Dec 3;274(49):34507-10 [10574907.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(5):1699-712 [10669747.001]
  • [Cites] Development. 2000 Mar;127(6):1315-24 [10683183.001]
  • [Cites] Cell. 2000 Apr 28;101(3):259-70 [10847681.001]
  • [Cites] Nat Cell Biol. 2000 Jul;2(7):407-14 [10878805.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] Ann N Y Acad Sci. 2000 Jun;910:106-18; discussion 118-20 [10911909.001]
  • [Cites] Hum Pathol. 2008 Nov;39(11):1582-9 [18703216.001]
  • [Cites] Biofactors. 2009 Jul-Aug;35(4):338-45 [19484742.001]
  • [Cites] Clin Cancer Res. 2009 Aug 15;15(16):5032-9 [19671848.001]
  • [Cites] Genet Med. 2009 Sep;11(9):599-610 [19652604.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):57-62 [11141479.001]
  • [Cites] Neuropathology. 2000 Sep;20(3):153-60 [11132929.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):747-55 [11257108.001]
  • [Cites] Trends Mol Med. 2001 Apr;7(4):157-62 [11286939.001]
  • [Cites] Genes Dev. 2001 Apr 15;15(8):968-80 [11316791.001]
  • [Cites] Biochem J. 2001 Jun 1;356(Pt 2):377-86 [11368764.001]
  • [Cites] J Biol Chem. 2001 Mar 9;276(10):7621-9 [11106646.001]
  • [Cites] J Biol Chem. 2001 Aug 31;276(35):33093-100 [11432873.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34728-37 [11457831.001]
  • [Cites] Oncogene. 2001 Oct 1;20(44):6309-14 [11607833.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):442-4 [11684412.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Dev Cell. 2001 Jul;1(1):63-72 [11703924.001]
  • [Cites] J Biol Chem. 2002 Jan 11;277(2):883-6 [11719502.001]
  • [Cites] Curr Opin Cell Biol. 2002 Feb;14(1):104-9 [11792551.001]
  • [Cites] Mol Cell Biol. 2002 Feb;22(4):1150-7 [11809806.001]
  • [Cites] Genomics. 2002 Jan;79(1):63-76 [11827459.001]
  • [Cites] Oncogene. 2002 Feb 14;21(8):1233-41 [11850843.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10332-6 [11756419.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10394-9 [11782491.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):354-62 [12118253.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Aug;3(8):586-99 [12154370.001]
  • [Cites] Cell. 2002 Aug 23;110(4):467-78 [12202036.001]
  • [Cites] Oncogene. 2002 Sep 5;21(39):5990-7 [12203111.001]
  • [Cites] Hum Mol Genet. 2002 Sep 15;11(19):2269-78 [12217955.001]
  • [Cites] Mol Cells. 2002 Aug 31;14(1):108-14 [12243339.001]
  • [Cites] Science. 2002 Oct 18;298(5593):597-600 [12228720.001]
  • [Cites] Hum Mol Genet. 2002 Dec 1;11(25):3167-78 [12444101.001]
  • [Cites] Hum Mol Genet. 2002 Dec 1;11(25):3179-89 [12444102.001]
  • [Cites] Genes Dev. 2002 Dec 1;16(23):3074-86 [12464636.001]
  • [Cites] Curr Opin Neurol. 2003 Feb;16(1):27-33 [12544854.001]
  • [Cites] J Neurochem. 2003 Jan;84(2):209-21 [12558984.001]
  • [Cites] Nat Cell Biol. 2003 May;5(5):410-21 [12717440.001]
  • [Cites] Genes Dev. 2003 May 1;17(9):1090-100 [12695331.001]
  • [Cites] J Pathol. 2003 Jul;200(4):448-64 [12845612.001]
  • [Cites] Oncogene. 2003 Jul 10;22(28):4398-405 [12853976.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):33334-41 [12807903.001]
  • [Cites] Cell. 2003 Aug 22;114(4):445-56 [12941273.001]
  • [Cites] J Biol Chem. 2003 Oct 17;278(42):41167-72 [12896975.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Dec;38(4):389-99 [14566860.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):841-9 [14580336.001]
  • [Cites] Int J Oncol. 2003 Dec;23(6):1493-500 [14612918.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):877-83 [14668818.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2717-24 [15087385.001]
  • [Cites] J Biol Chem. 2004 Apr 30;279(18):18559-66 [14981079.001]
  • [Cites] Nat Rev Cancer. 2004 Jul;4(7):528-39 [15229478.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):30265-73 [15123692.001]
  • [Cites] EMBO J. 2004 Sep 15;23(18):3677-88 [15343267.001]
  • [Cites] EMBO J. 1989 Dec 20;8(13):4133-42 [2591371.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8297-301 [1924289.001]
  • [Cites] J Cell Biol. 1991 Nov;115(4):1039-48 [1955455.001]
  • [Cites] J Cell Biol. 1993 Jan;120(1):129-39 [8416983.001]
  • [Cites] Q J Med. 1992 Aug;84(304):603-18 [1484939.001]
  • [Cites] Cell. 1993 Mar 12;72(5):791-800 [8453669.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • [Cites] Cancer Res. 1994 Jan 15;54(2):330-5 [7506121.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):185-92 [8162073.001]
  • [Cites] Curr Opin Cell Biol. 1994 Feb;6(1):136-41 [8167019.001]
  • [Cites] J Cell Biol. 1994 Jul;126(2):391-401 [7518464.001]
  • [Cites] Hum Mol Genet. 1994 Apr;3(4):559-64 [8069298.001]
  • [Cites] Curr Biol. 2009 Nov 3;19(20):1692-702 [19836237.001]
  • [Cites] J Cell Sci. 2009 Nov 15;122(Pt 22):4141-9 [19910496.001]
  • [Cites] Cancer Res. 2010 Mar 15;70(6):2455-64 [20197461.001]
  • [Cites] J Neurosurg. 2011 Feb;114(2):359-66 [19943731.001]
  • [Cites] J Cell Biol. 1996 May;133(4):843-52 [8666669.001]
  • [Cites] J Biol Chem. 1996 Aug 30;271(35):21049-53 [8702870.001]
  • [Cites] Oncogene. 1996 Sep 19;13(6):1239-47 [8808698.001]
  • [Cites] Hum Genet. 1996 Nov;98(5):534-8 [8882871.001]
  • [Cites] Curr Opin Cell Biol. 1997 Feb;9(1):70-5 [9013673.001]
  • [Cites] Genes Dev. 1997 May 15;11(10):1253-65 [9171370.001]
  • [Cites] Neurology. 1997 Jul;49(1):267-70 [9222206.001]
  • [Cites] J Biol Chem. 1997 Oct 31;272(44):27913-8 [9346940.001]
  • [Cites] J Cell Sci. 1997 Sep;110 ( Pt 18):2249-60 [9378774.001]
  • [Cites] Oncogene. 1997 Nov 13;15(20):2505-9 [9395247.001]
  • [Cites] J Cell Biol. 1998 Feb 23;140(4):885-95 [9472040.001]
  • [Cites] J Neurosci Res. 1998 Feb 1;51(3):403-15 [9486775.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):520-7 [17234759.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Oncogene. 2007 Feb 8;26(6):836-50 [16953231.001]
  • [Cites] Mol Cell Biol. 2007 Mar;27(6):2103-19 [17210637.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):331-8 [17277767.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):259-73 [17349583.001]
  • [Cites] Dev Biol. 2007 Apr 1;304(1):102-15 [17258190.001]
  • [Cites] Trends Cell Biol. 2007 May;17(5):222-9 [17442573.001]
  • [Cites] J Cell Biol. 2007 Jun 4;177(5):893-903 [17548515.001]
  • [Cites] Hum Mol Genet. 2007 Jul 15;16(14):1742-51 [17566081.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2007 Oct;15(5):341-6 [17823551.001]
  • [Cites] Cell. 2007 Sep 21;130(6):1120-33 [17889654.001]
  • [Cites] Mol Cell. 2007 Sep 21;27(6):962-75 [17889669.001]
  • [Cites] Mol Carcinog. 2007 Oct;46(10):865-71 [17538946.001]
  • [Cites] Nat Cell Biol. 2007 Oct;9(10):1199-207 [17891137.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2747-61 [17974916.001]
  • [Cites] Curr Biol. 2007 Nov 6;17(21):1864-70 [17964162.001]
  • [Cites] Biochim Biophys Acta. 2008 Jan;1785(1):32-54 [17980164.001]
  • [Cites] Biochim Biophys Acta. 2008 Jan;1784(1):3-15 [17881309.001]
  • [Cites] Br J Cancer. 2008 Jan 29;98(2):256-62 [17971776.001]
  • [Cites] Mol Cell Biol. 2008 Feb;28(4):1274-84 [18086884.001]
  • [Cites] Brain. 2008 Mar;131(Pt 3):606-15 [17940085.001]
  • [Cites] J Biol Chem. 2008 Feb 29;283(9):5496-509 [18158288.001]
  • [Cites] Mol Cell Biol. 2008 Apr;28(7):2426-36 [18227151.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):2592-8 [18413727.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):2789-94 [18413746.001]
  • [Cites] J Cell Mol Med. 2008 Apr;12(2):374-90 [18182063.001]
  • [Cites] EMBO J. 2008 Apr 23;27(8):1231-42 [18369314.001]
  • [Cites] Oncogene. 2008 Apr 24;27(19):2705-15 [17998937.001]
  • [Cites] Mol Cell. 2008 Apr 25;30(2):123-35 [18439892.001]
  • [Cites] Cell Signal. 2008 Jul;20(7):1237-47 [18255267.001]
  • [Cites] Cell. 2008 May 16;133(4):704-15 [18485877.001]
  • [Cites] Oncogene. 2008 May 22;27(23):3233-43 [18071304.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2806-12 [18539958.001]
  • [Cites] Exp Cell Res. 2008 Jul 1;314(11-12):2279-88 [18486129.001]
  • [Cites] Nat Cell Biol. 2008 Jul;10(7):837-48 [18568018.001]
  • [Cites] Cancer Res. 2008 Jul 15;68(14):5733-42 [18632626.001]
  • [Cites] Cell Stem Cell. 2008 Aug 7;3(2):221-7 [18682243.001]
  • [Cites] Dev Cell. 2008 Aug;15(2):209-19 [18694561.001]
  • [Cites] J Biol Chem. 2008 Oct 10;283(41):27534-46 [18640976.001]
  • [Cites] Neoplasia. 2008 Nov;10(11):1204-12 [18953429.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6751-60 [18980968.001]
  • [Cites] Mol Cell Biol. 2009 Mar;29(6):1472-86 [19103750.001]
  • [Cites] Dev Cell. 2009 Mar;16(3):433-44 [19289088.001]
  • [Cites] J Invest Dermatol. 2009 Jun;129(6):1321-4 [19434087.001]
  • [Cites] Trends Cell Biol. 2009 May;19(5):198-206 [19345106.001]
  • [Cites] Mol Cell Biol. 2009 Aug;29(15):4250-61 [19451225.001]
  • [Cites] Mol Cell Biol. 2009 Aug;29(15):4235-49 [19451229.001]
  • (PMID = 20491622.001).
  • [ISSN] 1875-5550
  • [Journal-full-title] Current protein & peptide science
  • [ISO-abbreviation] Curr. Protein Pept. Sci.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA135158-02; United States / NCI NIH HHS / CA / R01 CA135158-02; United States / NCI NIH HHS / CA / CA150355-01A1; United States / NCI NIH HHS / CA / R01 CA150355-01A1; United States / NCI NIH HHS / CA / 1R01CA150355-01A1; United States / NCI NIH HHS / CA / R01 CA135158; United States / NCI NIH HHS / CA / R01 CA150355; United States / NCI NIH HHS / CA / 1R01CA135158-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Neurofibromin 2
  • [Other-IDs] NLM/ NIHMS236013; NLM/ PMC2946555
  •  go-up   go-down


62. Galcheva-Gargova Z, Zhidkova N, Geisler S, Ozug J, Wudyka S, Gunay NS, Qi YW, Shriver Z, Venkataraman G: Overexpression of Merlin in B16F10 mouse melanoma cells reduces their metastatic activity: role of the cell surface heparan sulfate glycosaminoglycans. Int J Oncol; 2008 Jun;32(6):1237-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Merlin, the protein product of the neurofibromatosis type 2 gene (NF2) acts as a tumor suppressor in mice and humans.
  • In this study, melanoma B16F10 cells were engineered to overexpress the NF2 gene by establishing stable transductants.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18497985.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Neurofibromin 2; 9050-30-0 / Heparitin Sulfate
  •  go-up   go-down


63. Utermark T, Kaempchen K, Antoniadis G, Hanemann CO: Reduced apoptosis rates in human schwannomas. Brain Pathol; 2005 Jan;15(1):17-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Schwannomas, tumors originating from Schwann cells, represent a frequent neurological tumor and can occur both in a genetic disorder called neurofibromatosis type 2 (NF2) and sporadically.
  • In both cases the genetic background is identical as all schwannomas are caused by biallelic mutations in the tumor suppressor gene NF2 coding for merlin.
  • Mutations in this gene have also been found to be responsible for 50% to 60% of spontaneous and 100% of the NF2 associated meningiomas.
  • The NF2 gene product, merlin, links transmembrane proteins to the cytoskeleton and is involved in intracellular signaling processes.
  • It has previously been shown that reexpression of wild-type merlin in primary human schwannoma cells leads to an increase in the number of apoptotic cells.
  • Here, we report in vivo and in vitro evidence that the basal apoptosis rate of primary human schwannoma cells is reduced in comparison to that of normal Schwann cells, supporting the idea that in this benign tumor type, apoptosis has a role in tumorigenesis.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15779232.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


64. Bhatoe HS, Singh P, Dutta V: Intraventricular meningiomas: a clinicopathological study and review. Neurosurg Focus; 2006;20(3):E9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In this retrospective analysis, the authors describe the cases of 12 patients who had received a diagnosis of intraventricular meningioma and underwent surgery for the tumors.
  • Features of neurofibromatosis Type 2 were present in two of the women.
  • Nine of the tumors were located in the lateral ventricles, one was in the third ventricle, and two were in the fourth ventricle.
  • Excision was performed using the parietooccipital (trigonal) approach for lateral ventricle tumors, the transcortical-transventricular route for the third ventricle tumor, and suboccipital craniectomy for fourth ventricle tumors.
  • Although they are commonly seen in the lateral ventricles, they occur in the third and fourth ventricles as well.
  • Presentation is in the form of raised ICP with no localizing features; therefore the diagnosis is based on imaging studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16599425.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


65. Akinci A, Acaroglu G, Guven A, Degerliyurt A: Refractive errors in neurofibromatosis type 1 and type 2. Br J Ophthalmol; 2007 Jun;91(6):746-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractive errors in neurofibromatosis type 1 and type 2.
  • OBJECTIVE: To document the prevalence of refractive errors in patients with neurofibromatosis type 1 (NF1) and type 2 (NF2) and to compare it with that of age- and sex-matched controls.
  • METHODS: 82 patients with NF1, 21 patients with NF2 and 103 age- and sex-matched controls were evaluated in this prospective observational case-control study.
  • RESULTS: The prevalence of myopia was 23.1% in patients with NF1, 23.8% in patients with NF2 and 16.5% in age- and sex-matched controls.
  • These differences were significant (p<0.03, p<0.03), and adjusting for intelligence, education, height, weight and BMI increased the significance of this finding (p<0.001, p<0.001).
  • CONCLUSION: A high prevalence of myopia seems to be an additional feature of NF1 and NF2.
  • [MeSH-major] Neurofibromatosis 1 / complications. Neurofibromatosis 2 / complications. Refractive Errors / etiology


66. Zuccala' A, Di Nicolo' P, Fiorenza S, Lifrieri F, Rapana' R: [The sympathetic system and neuroendocrine hypertension]. G Ital Nefrol; 2008 Mar-Apr;25(2):203-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sporadic pheochromocytoma is a rare tumor that should be taken into account in patients with hypertensive crisis, arrhythmias, and panic disorder.
  • Familial pheochromocytoma is frequently found in subjects with von Hippel-Lindau disease, multiple endocrine neoplasia type II, neurofibromatosis, and SDHD gene mutations.
  • Plasma free metanephrines have been shown to have high sensitivity and specificity in the biochemical diagnosis of sporadic and familial pheochromocytoma.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18350500.001).
  • [ISSN] 0393-5590
  • [Journal-full-title] Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
  • [ISO-abbreviation] G Ital Nefrol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 49
  •  go-up   go-down


67. Evans DG, Maher ER, Baser ME: Age related shift in the mutation spectra of germline and somatic NF2 mutations: hypothetical role of DNA repair mechanisms. J Med Genet; 2005 Aug;42(8):630-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age related shift in the mutation spectra of germline and somatic NF2 mutations: hypothetical role of DNA repair mechanisms.
  • We compared the ratio of frameshift to nonsense mutations in three diseases that are related to the NF2 tumour suppressor gene: classic neurofibromatosis 2 (NF2), caused by germline NF2 mutations; mosaic NF2; and unilateral sporadic vestibular schwannoma (USVS), caused by somatic NF2 inactivation.
  • Nonsense mutations predominated in both classic and mosaic NF2, but the ratio of nonsense to frameshift mutations was reversed in USvs. Moreover, in USVS patients, the ratio of somatic frameshift to nonsense mutations increased significantly with increasing age at diagnosis.
  • Similar studies for other familial cancer genes may provide further evidence for this hypothesis.
  • [MeSH-major] Codon, Nonsense. DNA Repair / physiology. Frameshift Mutation. Genes, Neurofibromatosis 2. Germ-Line Mutation
  • [MeSH-minor] Age Factors. Genetic Predisposition to Disease. Humans. Mosaicism. Neuroma, Acoustic / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2000 Jan;66(1):84-91 [10631138.001]
  • [Cites] Nat Med. 1999 Sep;5(9):1071-5 [10470088.001]
  • [Cites] Genetics. 2000 Jul;155(3):1359-67 [10880494.001]
  • [Cites] Am J Otol. 2000 Sep;21(5):690-4 [10993460.001]
  • [Cites] Environ Mol Mutagen. 2000;36(4):301-11 [11152563.001]
  • [Cites] Genes Cells. 2001 May;6(5):441-54 [11380622.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):6991-5 [11585722.001]
  • [Cites] Mol Cell Biol. 2001 Nov;21(22):7587-600 [11604495.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2920-6 [11753967.001]
  • [Cites] Ann N Y Acad Sci. 2001 Apr;928:113-20 [11795502.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(7):2410-8 [11884623.001]
  • [Cites] Mutat Res. 2002 Mar 20;500(1-2):135-45 [11890943.001]
  • [Cites] Gene. 2002 May 1;289(1-2):41-8 [12036582.001]
  • [Cites] Mech Ageing Dev. 2002 Apr 30;123(8):907-15 [12044939.001]
  • [Cites] Nucleic Acids Res. 2002 Aug 15;30(16):3566-73 [12177298.001]
  • [Cites] Hum Mutat. 2003 Jan;21(1):12-27 [12497628.001]
  • [Cites] J Med Genet. 2003 Jun;40(6):459-63 [12807969.001]
  • [Cites] Oncogene. 2003 Jul 3;22(27):4257-65 [12833148.001]
  • [Cites] Hum Mutat. 2004 Feb;23(2):134-46 [14722917.001]
  • [Cites] Nat Cell Biol. 2004 Feb;6(2):168-70 [14755273.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):29-39 [15000147.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 18;101(20):7624-9 [15123826.001]
  • [Cites] Biochim Biophys Acta. 2004 Aug 12;1679(2):95-106 [15297143.001]
  • [Cites] Am J Hum Genet. 2004 Aug;75(2):231-9 [15190457.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Aug 20;321(2):455-61 [15358197.001]
  • [Cites] Q J Med. 1992 Aug;84(304):603-18 [1484939.001]
  • [Cites] Arch Toxicol. 1997;71(5):332-5 [9137812.001]
  • [Cites] Hum Mutat. 1999;13(6):464-75 [10408776.001]
  • [Cites] Mutat Res. 2000 Apr 28;459(3):195-202 [10812331.001]
  • (PMID = 16061561.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Codon, Nonsense
  • [Other-IDs] NLM/ PMC1736122
  •  go-up   go-down


68. Franzin A, Spatola G, Serra C, Picozzi P, Medone M, Milani D, Castellazzi P, Mortini P: Evaluation of hearing function after Gamma Knife surgery of vestibular schwannomas. Neurosurg Focus; 2009 Dec;27(6):E3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of hearing function after Gamma Knife surgery of vestibular schwannomas.
  • OBJECT: Due to technological advances in neuroradiology in recent years, incidental diagnoses of vestibular schwannomas (VSs) have increased.
  • METHODS: Of all patients treated in the authors' hospital between 2001 and 2007, they retrospectively studied 50 patients with a unilateral VS in whom there was serviceable hearing (Gardner-Robertson [GR] Class I or II).
  • Additional inclusion criteria were: no Type 2 neurofibromatosis, no previous treatment, and at least 6 months' follow-up of neuroradiological and audiological data.
  • Serviceable hearing was preserved in 34 patients (68%): 21 (62%) with GR Class I hearing and 13 (38%) with GR Class II hearing.
  • In 19 (58%) of 33 patients with GR Class I function before GKS the same class was maintained posttreatment; 29 (88%) maintained functional hearing (GR Class I or II).
  • Significant prognostic factors for maintaining serviceable hearing were GR Class I function before treatment, symptoms at presentation, patient age younger than 54 years, and Koos Stage T1 disease.
  • The prescribed dose of 13 Gy appears to represent an excellent compromise between controlling the disease and preserving auditory function.
  • [MeSH-major] Hearing Loss / prevention & control. Neuroma, Acoustic / surgery. Postoperative Complications / prevention & control. Radiosurgery / methods

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19951056.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Yu H, Ye L, Mansel RE, Zhang Y, Jiang WG: Clinical implications of the influence of Ehm2 on the aggressiveness of breast cancer cells through regulation of matrix metalloproteinase-9 expression. Mol Cancer Res; 2010 Nov;8(11):1501-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ehm2, a member of NF2/ERM/4.1 superfamily, has been indicated in disease progression and metastasis of prostate cancer.
  • Higher levels of Ehm2 transcripts were correlated with disease progression, metastasis, and poor prognosis.
  • Disease-free survival of the patients with lower levels of Ehm2 was 135.8 (95% confidence interval, 125.1-146.5) months, significantly longer compared with 102.5 (95% confidence interval, 78.7-126.4) months of patients with higher levels of Ehm2 expression (P = 0.039).

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • (PMID = 21047774.001).
  • [ISSN] 1557-3125
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytoskeletal Proteins; 0 / EPB41L4B protein, human; 0 / RNA, Catalytic; 0 / hammerhead ribozyme; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


70. Mazzoni A, Dubey SP, Poletti AM, Colombo G: Sporadic acoustic neuroma in pediatric patients. Int J Pediatr Otorhinolaryngol; 2007 Oct;71(10):1569-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic acoustic neuroma in pediatric patients.
  • OBJECTIVE: Sporadic acoustic neuroma, usually occur between the ages of 40 and 70 years, are very rare in children.
  • We review the experiences of 10 cases of sporadic (non-NF2) acoustic neuromas in pediatric patients.
  • Among these almost 900 cases were acoustic neuromas.
  • Postoperatively seven cases the facial nerve recovered to grade I, and one each to grade II and grade VI of House-Brackmann classification.
  • [MeSH-major] Neuroma, Acoustic / epidemiology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Hearing Loss, Sensorineural / diagnosis. Hearing Loss, Sensorineural / epidemiology. Humans. Incidence. Male. Paresis / diagnosis. Paresis / epidemiology. Paresis / etiology. Postoperative Complications. Prevalence. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17643497.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


71. Martinez-Glez V, Bello MJ, Franco-Hernandez C, De Campos JM, Isla A, Vaquero J, Rey JA: Mutational analysis of the DAL-1/4.1B tumour-suppressor gene locus in meningiomas. Int J Mol Med; 2005 Oct;16(4):771-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The DAL-1/41B gene (differentially expressed in adenocarcinoma of the lung), located in the chromosome 18p11.3 region, belongs to the protein family 4.1 (membrane-associated proteins), which includes the product of the NF2 gene (merlin), and the proteins, ezrin, radixin, and moesin.
  • We found the following sequence variations; Ala555Thr (G1663A in exon 13) and Thr950Lys (C2849A in exon 19) in two cases each, and one case with a 5pb deletion (del taaaa) in intron 18.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142420.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / EPB41L3 protein, human; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


72. Bosch MM, Wichmann WW, Boltshauser E, Landau K: Optic nerve sheath meningiomas in patients with neurofibromatosis type 2. Arch Ophthalmol; 2006 Mar;124(3):379-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optic nerve sheath meningiomas in patients with neurofibromatosis type 2.
  • OBJECTIVE: To determine the prevalence of optic nerve sheath meningiomas (ONSMs) in patients with neurofibromatosis type 2 (NF2).
  • METHODS: An observational retrospective case series of 30 consecutive patients with NF2 referred to an academic ophthalmology unit from November 1, 1991, through August 31, 2003.
  • Diagnosis of ONSM was made based on typical neuroradiologic and clinical features in 7 patients and on histologic criteria in 1.
  • RESULTS: Eight of 30 patients harbored unilateral (n = 6) or bilateral (n = 2) ONSMs.
  • CONCLUSIONS: There is a strong association between ONSMs and NF2 that parallels the well-known association of optic nerve gliomas with NF1.
  • Physicians should be aware of the possibility that patients with ONSMs may also have NF2.
  • [MeSH-major] Meningioma / diagnosis. Neurofibromatosis 2 / diagnosis. Optic Nerve Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16534058.001).
  • [ISSN] 0003-9950
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Ruggieri M, Iannetti P, Polizzi A, La Mantia I, Spalice A, Giliberto O, Platania N, Gabriele AL, Albanese V, Pavone L: Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients. Neuropediatrics; 2005 Feb;36(1):21-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients.
  • BACKGROUND: Neurofibromatosis type 2 (NF2) is an autosomal dominant disease characterised by the development of multiple nervous system tumours, ocular abnormalities, and skin tumours.
  • Although classically considered a disease of adults, initial signs and/or symptoms may be evident in childhood and are often unrecognised.
  • OBJECTIVES: The aim of this study was to identify the earliest clinical presentations of NF2 and to characterise the clinical course and outcome in children with NF2.
  • METHODS: We have performed a retrospective (years 1990-1998) and prospective (years 1998-2004) study of 24 patients (10 males, 14 females; currently aged 4 to 22 years) fulfilling the revised (Manchester) NF2 criteria seen at the Universities of Catania and Rome, Italy.
  • RESULTS: Causes of referral prior to a definitive diagnosis of NF2 were:.
  • 3) Neurological dysfunction: seizures secondary to intracranial meningioma (n = 1) or vestibular schwannomas (VS) (n = 1), neurological dysfunction related to brainstem and/or spinal cord tumours (n = 7), isolated and multiple cranial nerve deficits (n = 10), and peripheral neuropathy secondary to schwannomas (n = 4);.
  • Molecular genetic analysis of the NF2 gene revealed typical truncating mutations in all the 5 familial cases and in 2/10 sporadic cases analysed.
  • CONCLUSIONS: Children with NF2 often first come to medical attention because of ocular, subtle skin, or neurological problems the significance of which is realised when they later present with more classical symptoms due to bilateral VS or other intracranial tumours.
  • [MeSH-major] Neurofibromatosis 2 / physiopathology. Otorhinolaryngologic Diseases / etiology


74. Patil S, Perry A, Maccollin M, Dong S, Betensky RA, Yeh TH, Gutmann DH, Stemmer-Rachamimov AO: Immunohistochemical analysis supports a role for INI1/SMARCB1 in hereditary forms of schwannomas, but not in solitary, sporadic schwannomas. Brain Pathol; 2008 Oct;18(4):517-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The INI1/SMARCB1 protein product (INI1), a component of a transcription complex, was recently implicated in the pathogenesis of schwannomas in two members of a single family with familial schwannomatosis.
  • To determine if this finding could be extended to all tumors arising in familial schwannomatosis, and how it compares with other multiple schwannoma syndromes [sporadic schwannomatosis and neurofibromatosis 2 (NF2)] as well as to sporadic, solitary schwannomas, we performed an immunohistochemistry analysis on 45 schwannomas from patients with multiple schwannoma syndromes and on 38 solitary, sporadic schwannomas from non-syndromic patients.
  • A mosaic pattern of INI1 expression was seen in 93% of tumors from familial schwannomatosis patients, 55% of tumors from sporadic schwannomatosis, 83% of NF2-associated tumors and only 5% of solitary, sporadic schwannomas.
  • These results confirm a role for INI1/SMARCB1 in multiple schwannoma syndromes and suggest that a different pathway of tumorigenesis occurs in solitary, sporadic tumors.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2001 May 28;20(24):3067-75 [11420722.001]
  • [Cites] Neurology. 2003 Jun 24;60(12):1968-74 [12821741.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Sep;17(1):45-55 [8889506.001]
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [Cites] Am J Hum Genet. 2007 Apr;80(4):805-10 [17357086.001]
  • [Cites] Neurology. 2005 Jun 14;64(11):1838-45 [15955931.001]
  • [Cites] Mod Pathol. 2005 Jul;18(7):951-8 [15761491.001]
  • [Cites] Mod Pathol. 2006 May;19(5):717-25 [16528370.001]
  • [Cites] Pediatr Blood Cancer. 2006 Sep;47(3):279-84 [16261613.001]
  • [Cites] Am J Hum Genet. 1997 Dec;61(6):1293-302 [9399891.001]
  • (PMID = 18422762.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS024279-20A29010; United States / NINDS NIH HHS / NS / P01 NS024279-20A29010
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / Genetic Markers; 0 / Neurofibromin 2; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  • [Other-IDs] NLM/ NIHMS114873; NLM/ PMC2743242
  •  go-up   go-down


75. Zhao ZS, Manser E: Do PAKs make good drug targets? F1000 Biol Rep; 2010;2:70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The genetic loss of NF2 (neurofibromatosis type 2) leading to increased cell proliferation through a Ras-Rac-PAK pathway may represent a good test system to analyze this new PAK inhibitor.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21173843.001).
  • [ISSN] 1757-594X
  • [Journal-full-title] F1000 biology reports
  • [ISO-abbreviation] F1000 Biol Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2989626
  •  go-up   go-down


76. Michalowski MB, de Fraipont F, Michelland S, Entz-Werle N, Grill J, Pasquier B, Favrot MC, Plantaz D: Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genet Cytogenet; 2006 Apr 1;166(1):74-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ependymomas (EP) represent the third most frequent type of central nervous system (CNS) tumor of childhood, after astrocytomas and medulloblastomas.
  • The present objective was, for a sample of 27 children with intracranial EP and 7 with CPP, to describe and compare the methylation status of 19 genes (with current HUGO symbol, if any): p15INK4a (CDKN2B), p16INK4a and p14ARF (both CDKN2A), APC, RB1, RASSF1A (RASSF1), BLU (ZMYND10) FHIT, RARB, MGMT, DAPK (DAPK1), ECAD (CDH1), CASP8, TNFRSF10C, TNFRSF10D, FLIP (CFLAR), INI1 (SMARCB1), TIMP3, and NF2.


77. Holland K, Kaye AH: Spinal tumors in neurofibromatosis-2: management considerations - a review. J Clin Neurosci; 2009 Feb;16(2):169-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal tumors in neurofibromatosis-2: management considerations - a review.
  • Neurofibromatosis Type 2 (NF-2) is a distinct clinical entity, characterized by multiple intracranial and spinal tumors.
  • While bilateral vestibular schwannomas are the pathological hallmark of the disease, significant morbidity in NF-2 is attributable to the presence of both intramedullary and extramedullary spinal tumors.
  • With the advent of MRI as a screening modality, multiple, extensive spinal tumors in the NF-2 population are often seen, which may be clinically quiescent at the time of initial diagnosis.
  • All NF-2 patients should have routine screening with full spinal MRI at the time of diagnosis, regardless of symptoms.
  • [MeSH-major] Neurofibromatosis 2 / diagnosis. Neurofibromatosis 2 / therapy. Spinal Neoplasms / diagnosis. Spinal Neoplasms / therapy

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19101145.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Scotland
  • [Number-of-references] 44
  •  go-up   go-down


78. Hadfield KD, Newman WG, Bowers NL, Wallace A, Bolger C, Colley A, McCann E, Trump D, Prescott T, Evans DG: Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J Med Genet; 2008 Jun;45(6):332-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis.
  • BACKGROUND: Schwannomatosis is a rare condition characterised by multiple schwannomas and lack of involvement of the vestibular nerve.
  • A recent report identified bi-allelic mutations in the SMARCB1/INI1 gene in a single family with schwannomatosis.
  • We aimed to establish the contribution of the SMARCB1 and the NF2 genes to sporadic and familial schwannomatosis in our cohort.
  • METHODS: We performed DNA sequence and dosage analysis of SMARCB1 and NF2 in 28 sporadic cases and 15 families with schwannomatosis.
  • In addition, in all affected individuals with SMARCB1 mutations and available tumour tissue, we detected bi-allelic somatic inactivation of the NF2 gene.
  • CONCLUSION: In contrast to the recent report where no NF2 mutations were identified in a schwannomatosis family with SMARCB1 mutations, in our cohort, a four hit model with mutations in both SMARCB1 and NF2 define a subset of patients with schwannomatosis.


79. Roser F, Ebner FH, Ritz R, Samii M, Tatagiba MS, Nakamura M: Management of skull based meningiomas in the elderly patient. J Clin Neurosci; 2007 Mar;14(3):224-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The demographic evolution of Western society together with availability of modern imaging techniques leads to an increasing diagnosis of meningioma patients over 70 years of age.
  • DESIGN: Forty-three patients aged over 70 years were analyzed and matched in a retrospective study with a younger group of 89 patients according to tumour size, histology, symptoms, recurrence and presence of neurofibromatosis II.
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Humans. Middle Aged. Morbidity. Neoplasm Recurrence, Local / mortality. Neurofibromatosis 2 / mortality. Neurofibromatosis 2 / surgery. Patient Selection. Postoperative Complications / mortality. Quality of Life. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17258130.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


80. Kobayashi H, Ishii N, Murata J, Saito H, Kubota KC, Nagashima K, Iwasaki Y: Cystic meningioangiomatosis. Pediatr Neurosurg; 2006;42(5):320-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 14-year-old boy without any stigmata of neurofibromatosis type 2 presented intractable complex partial and generalized seizures since the age of 12 years.

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16902347.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


81. Rice JM: Inducible and transmissible genetic events and pediatric tumors of the nervous system. J Radiat Res; 2006;47 Suppl B:B1-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors of the nervous system most often occur in both children and adults as sporadic events with no family history of the disease, but they are also among the clinical manifestations of a significant number of familial cancer syndromes, including familial retinoblastoma, neurofibromatosis 1 and 2, tuberous sclerosis, and Cowden, Turcot, Li-Fraumeni and nevoid basal cell carcinoma (Gorlin) syndromes.
  • These genes include RB1, NF1, NF2, TSC1, TSC2, TP53, PTEN, APC, hMLH1, hPSM2, and PTCH, most of which function as tumor suppressor genes.


82. Feucht M, Kluwe L, Mautner VF, Richard G: Correlation of nonsense and frameshift mutations with severity of retinal abnormalities in neurofibromatosis 2. Arch Ophthalmol; 2008 Oct;126(10):1376-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of nonsense and frameshift mutations with severity of retinal abnormalities in neurofibromatosis 2.
  • BACKGROUND: Neurofibromatosis 2 (NF2) is an autosomal dominant disease that is characterized by nervous system tumors and ocular abnormalities.
  • OBJECTIVE: To investigate genotype-phenotype correlations demonstrated for NF2-associated nervous system tumors, cataracts, and retinal lesions.
  • METHODS: Forty-eight patients with NF2 from a tertiary neurological referral center underwent screening for constitutional NF2 mutations with multiple screening methods.
  • CONCLUSIONS: To our knowledge, this is the first genetic, clinical, and angiographic characterization of retinal abnormalities in NF2.
  • Clinical Relevance Retinal abnormalities, which can be revealed by means of fluorescein angiography, are more common in patients with NF2 who have nonsense or frameshift mutations.
  • [MeSH-major] Fluorescein Angiography. Frameshift Mutation. Genes, Neurofibromatosis 2. Neurofibromatosis 2 / epidemiology. Neurofibromatosis 2 / genetics. Retinal Diseases / epidemiology. Retinal Diseases / genetics
  • [MeSH-minor] Adolescent. Adult. Age of Onset. Analysis of Variance. Cataract / diagnosis. Cataract / genetics. Causality. Child. Codon, Nonsense. Cohort Studies. Comorbidity. Confidence Intervals. Female. Genetic Predisposition to Disease. Genetic Testing. Genotype. Humans. Logistic Models. Male. Middle Aged. Odds Ratio. Phenotype. Severity of Illness Index

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Retinal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18852415.001).
  • [ISSN] 1538-3601
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon, Nonsense
  •  go-up   go-down


83. McLaughlin ME, Pepin SM, Maccollin M, Choopong P, Lessell S: Ocular pathologic findings of neurofibromatosis type 2. Arch Ophthalmol; 2007 Mar;125(3):389-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular pathologic findings of neurofibromatosis type 2.
  • OBJECTIVE: To gain insight into the pathogenesis of neurofibromatosis type 2 (NF2) by investigating the ocular manifestations of this disease.
  • METHODS: Using standard histologic techniques, immunohistochemistry, and electron microscopy, we described the ocular pathologic findings of a 34-year-old woman who died from complications of NF2.
  • RESULTS: We identified 3 types of NF2-associated lesions: juvenile posterior subcapsular cataracts, epiretinal membranes, and an intrascleral schwannoma.
  • CONCLUSIONS: Our analysis indicated that dysplastic lens cells accumulate just anterior to the posterior lens capsule in juvenile posterior subcapsular cataracts and that dysplastic Müller cells may be a major component of NF2-associated epiretinal membranes.
  • Clinical Relevance Our findings suggest that a subset of glial cells with epithelial features (Schwann cells, ependymal cells, and Müller cells) may be particularly sensitive to loss of the NF2 gene.
  • Understanding the molecular basis for this sensitivity may lead to novel strategies for treating NF2.
  • [MeSH-major] Cataract / pathology. Epiretinal Membrane / pathology. Eye Neoplasms / pathology. Neurilemmoma / pathology. Neurofibromatosis 2 / pathology. Scleral Diseases / pathology


84. Ahronowitz I, Xin W, Kiely R, Sims K, MacCollin M, Nunes FP: Mutational spectrum of the NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings. Hum Mutat; 2007 Jan;28(1):1-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutational spectrum of the NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings.
  • The NF2 tumor suppressor gene on chromosome 22 is a member of the protein 4.1 family of cytoskeletal elements.
  • A number of single- and multiple-tumor phenotypes have been linked to alterations of NF2 since its characterization in 1993.
  • We present a meta-analysis of 967 constitutional and somatic NF2 alterations from 93 published reports, along with 59 additional unpublished events identified in our laboratory and 115 alterations identified in clinical samples submitted to the Massachusetts General Hospital (MGH) Neurogenetics DNA Diagnostic Laboratory.
  • There was no statistically significant difference in mutation type or exon distribution between published constitutional events and those found by the clinical laboratory.
  • [MeSH-major] Genes, Neurofibromatosis 2. Molecular Diagnostic Techniques / methods. Mutation

  • Genetics Home Reference. consumer health - NF2 gene.
  • COS Scholar Universe. author profiles.
  • SciCrunch. OMIM: Data: Gene Annotation .
  • SciCrunch. Clinical Genomic Database: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published 2006 Wiley-Liss, Inc.
  • (PMID = 16983642.001).
  • [ISSN] 1098-1004
  • [Journal-full-title] Human mutation
  • [ISO-abbreviation] Hum. Mutat.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / 1 R01 NS40527
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


85. Denayer E, Brems H, de Cock P, Evans GD, Van Calenbergh F, Bowers N, Sciot R, Debiec-Rychter M, Vermeesch JV, Fryns JP, Legius E: Pathogenesis of vestibular schwannoma in ring chromosome 22. BMC Med Genet; 2009;10:97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathogenesis of vestibular schwannoma in ring chromosome 22.
  • Clinical features of neurofibromatosis type 1 and 2 as well as different tumour types have been reported in patients with ring chromosome 22.
  • At the age of 20 years she was diagnosed with a unilateral vestibular schwannoma.
  • Tumour cells were analyzed by karyotyping, array CGH and NF2 mutation analysis.
  • Genetic analysis of vestibular schwannoma tissue revealed loss of the ring chromosome 22 and a somatic second hit in the NF2 gene on the remaining chromosome 22.
  • CONCLUSION: We conclude that tumours can arise by the combination of loss of the ring chromosome and a pathogenic NF2 mutation on the remaining chromosome 22 in patients with ring chromosome 22.
  • Our findings indicate that patients with a ring 22 should be monitored for NF2-related tumours starting in adolescence.
  • [MeSH-major] Chromosomes, Human, Pair 22. Neuroma, Acoustic / genetics. Ring Chromosomes
  • [MeSH-minor] Adult. Female. Genes, Neurofibromatosis 1. Genes, Neurofibromatosis 2. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Magnetic Resonance Imaging. Mutation. Oligonucleotide Array Sequence Analysis. Phenotype. Sequence Analysis, DNA


86. Ye K: Phosphorylation of merlin regulates its stability and tumor suppressive activity. Cell Adh Migr; 2007 Oct-Dec;1(4):196-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The neurofibromatosis-2 (NF2) tumor suppressor protein, merlin or schwannomin, inhibits cell proliferation by modulating the growth activities of its binding partners, including the cell surface glycoprotein CD44, membrane-cytoskeleton linker protein ezrin and PIKE (PI 3-kinase enhancer) GTPase, etc.
  • This finding demonstrates a negative feed-back loop from merlin/PIKE-L/PI 3-kinase to Akt in tumors- The proliferation repressive activity of merlin is also partially regulated by S518 phosphorylation- Thus, Akt-mediated merlin T230/S315 phosphorylation, combined with S518 phosphorylation by PAK and PKA, provides new insight into abrogating merlin function in the absence of merlin mutational inactivation.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1997 Nov 13;15(20):2505-9 [9395247.001]
  • [Cites] Hum Mol Genet. 1998 Mar;7(3):335-45 [9466988.001]
  • [Cites] J Neurosci Res. 1998 Feb 1;51(3):403-15 [9486775.001]
  • [Cites] Nat Genet. 1998 Apr;18(4):354-9 [9537418.001]
  • [Cites] Oncogene. 2004 Nov 4;23(52):8447-54 [15378014.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18200-5 [15598747.001]
  • [Cites] Oncogene. 2006 Sep 28;25(44):5960-8 [16652148.001]
  • [Cites] Nat Cell Biol. 2007 Oct;9(10):1199-207 [17891137.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(5):1699-712 [10669747.001]
  • [Cites] J Neurosci Res. 2000 Nov 15;62(4):491-502 [11070492.001]
  • [Cites] Cell. 2000 Dec 8;103(6):919-30 [11136977.001]
  • [Cites] Genes Dev. 2001 Apr 15;15(8):968-80 [11316791.001]
  • [Cites] Dev Cell. 2001 Jul;1(1):63-72 [11703924.001]
  • [Cites] J Biol Chem. 2002 Jan 11;277(2):883-6 [11719502.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10394-9 [11782491.001]
  • [Cites] Hum Mol Genet. 2002 Dec 1;11(25):3167-78 [12444101.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):580-7 [14724586.001]
  • [Cites] J Biol Chem. 2004 Apr 30;279(18):18559-66 [14981079.001]
  • [Cites] Adv Neurol. 1981;29:57-65 [6798843.001]
  • [Cites] Cell. 1993 Mar 12;72(5):791-800 [8453669.001]
  • (PMID = 19262146.001).
  • [ISSN] 1933-6926
  • [Journal-full-title] Cell adhesion & migration
  • [ISO-abbreviation] Cell Adh Migr
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA117872
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / CD44 protein, human; 0 / GTPase-Activating Proteins; 0 / Neurofibromin 2; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / p21-Activated Kinases; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 3.6.1.- / AGAP2 protein, human; EC 3.6.1.- / GTP-Binding Proteins
  • [Number-of-references] 21
  • [Other-IDs] NLM/ PMC2634106
  •  go-up   go-down


87. Benesch M, Weber-Mzell D, Gerber NU, von Hoff K, Deinlein F, Krauss J, Warmuth-Metz M, Kortmann RD, Pietsch T, Driever PH, Quehenberger F, Urban C, Rutkowski S: Ependymoma of the spinal cord in children and adolescents: a retrospective series from the HIT database. J Neurosurg Pediatr; 2010 Aug;6(2):137-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between 1991 and 2007, 29 patients (12 male and 17 female, median age at diagnosis 13.6 years) with primary spinal cord ependymoma (myxopapillary ependymoma WHO Grade I, II, and III tumors in 6, 17, and 6 patients, respectively) were identified.
  • Four patients had neurofibromatosis Type 2.
  • Seven patients (24.1%) developed progressive disease or relapse, 2 after gross-total resection (GTR) and 5 after incomplete resection or biopsy.
  • One patient with anaplastic ependymoma (WHO Grade III) died 65 months after diagnosis of disease progression.
  • [MeSH-minor] Adolescent. Austria. Biopsy. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Disability Evaluation. Disease Progression. Female. Follow-Up Studies. Germany. Humans. Male. Neurofibromatosis 2 / diagnosis. Neurofibromatosis 2 / drug therapy. Neurofibromatosis 2 / pathology. Neurofibromatosis 2 / radiotherapy. Neurofibromatosis 2 / surgery. Postoperative Complications / diagnosis. Postoperative Complications / mortality. Prospective Studies. Radiotherapy, Adjuvant. Registries. Survival Rate

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20672934.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


88. Walcott BP, Sivarajan G, Bashinskaya B, Anderson DE, Leonetti JP, Origitano TC: Sporadic unilateral vestibular schwannoma in the pediatric population. Clinical article. J Neurosurg Pediatr; 2009 Aug;4(2):125-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic unilateral vestibular schwannoma in the pediatric population. Clinical article.
  • OBJECT: Vestibular schwannomas (VSs) are rare in the pediatric population.
  • Most often, these lesions manifest as a bilateral disease process in the setting of neurofibromatosis Type 2.
  • Clinical outcomes were reviewed with emphasis on facial nerve function and follow-up for signs and symptoms of a heritable disorder.
  • The average tumor size was 4.57 cm, with an average duration of symptoms prior to definitive diagnosis of 31.2 months.
  • At a follow-up average of 6.3 years (range 1-12 years), 100% of patients demonstrated good facial function (House-Brackmann Grade I or II).
  • No patient in this cohort demonstrated symptoms, objective signs, or genetic analysis indicating the presence of neurofibromatosis Type 2.
  • CONCLUSIONS: Diagnosis and management of sporadic, unilateral VSs in children is complicated by clinical presentations and surgical challenges unique from their adult counterparts.
  • [MeSH-major] Facial Nerve / physiopathology. Neuroma, Acoustic / surgery
  • [MeSH-minor] Adolescent. Child. Cohort Studies. Ear, Inner. Female. Humans. Male. Neurofibromatosis 2 / pathology. Recovery of Function. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19645545.001).
  • [ISSN] 1933-0707
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Pitchford CW, Schwartz HS, Atkinson JB, Cates JM: Soft tissue perineurioma in a patient with neurofibromatosis type 2: a tumor not previously associated with the NF2 syndrome. Am J Surg Pathol; 2006 Dec;30(12):1624-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue perineurioma in a patient with neurofibromatosis type 2: a tumor not previously associated with the NF2 syndrome.
  • Neoplasms that commonly affect patients with neurofibromatosis type 2 (NF2) include schwannomas, meningiomas, astrocytomas, ependymomas, and neurofibromas.
  • As in both NF2-associated and sporadic cases of schwannoma and meningioma, perineuriomas often harbor mutations or deletions of the NF2 gene.
  • However, perineuriomas have not previously been reported in the clinical setting of NF2.
  • A 30-year-old man with a history of bilateral vestibular schwannomas, a parasagittal meningioma, an intraspinal ependymoma, and multiple other neoplasms involving both cranial and peripheral nerves (thereby fulfilling the diagnostic criteria for NF2) presented with an enlarging thigh mass.
  • The diagnosis of cellular soft tissue perineurioma was confirmed by both immunohistochemical and ultrastructural analysis.
  • This case represents the first report of a soft tissue perineurioma arising in the setting of NF2.
  • [MeSH-major] Nerve Sheath Neoplasms / complications. Neurofibromatosis 2 / complications. Soft Tissue Neoplasms / complications
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Cytoplasm / ultrastructure. Diagnosis, Differential. Humans. Male. Neoplasms, Multiple Primary. Peripheral Nervous System Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122521.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


90. Skarzynski H, Lorens A, Kochanek K, Mrowka M, Behr R: Bilateral auditory brainstem implantation in a patient with neurofibromatosis type II. Cochlear Implants Int; 2010 Jun;11 Suppl 1:88-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral auditory brainstem implantation in a patient with neurofibromatosis type II.
  • [MeSH-major] Auditory Brain Stem Implantation / methods. Neurofibromatosis 2 / surgery. Neuroma, Acoustic / surgery. Neurosurgical Procedures / methods

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21756589.001).
  • [ISSN] 1754-7628
  • [Journal-full-title] Cochlear implants international
  • [ISO-abbreviation] Cochlear Implants Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


91. Slattery WH 3rd, Fisher LM, Hitselberger W, Friedman RA, Brackmann DE: Hearing preservation surgery for neurofibromatosis Type 2-related vestibular schwannoma in pediatric patients. J Neurosurg; 2007 Apr;106(4 Suppl):255-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hearing preservation surgery for neurofibromatosis Type 2-related vestibular schwannoma in pediatric patients.
  • OBJECT: The authors reviewed the proportion of pediatric patients with neurofibromatosis Type 2 (NF2) in whom hearing was preserved after middle fossa resection of vestibular schwannoma (VS).
  • METHODS: In this retrospective chart review the authors examined the cases of 35 children with NF2 who had undergone middle fossa resection (47 surgeries) between 1992 and 2004 in a neurotological tertiary care center.
  • Facial nerve function was good (House-Brackmann Grades I or II) in 81% of the patients.
  • Twelve patients had bilateral middle fossa resections; in nine (75%) of these patients hearing was maintained postoperatively in both ears.
  • CONCLUSIONS: More than half of the children with NF2 in the authors' cohort experienced hearing preservation after middle fossa resection was performed for vs. The authors recommend this approach for preserving hearing in children with NF2.
  • [MeSH-major] Facial Nerve / physiopathology. Hearing / physiology. Neurofibromatosis 2 / surgery. Neuroma, Acoustic / surgery


92. Scoles DR, Yong WH, Qin Y, Wawrowsky K, Pulst SM: Schwannomin inhibits tumorigenesis through direct interaction with the eukaryotic initiation factor subunit c (eIF3c). Hum Mol Genet; 2006 Apr 1;15(7):1059-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The neurofibromatosis 2 (NF2) tumor suppressor protein, schwannomin or merlin, is commonly lost upon NF2 gene mutation in benign human brain tumors.
  • Consequently, eIF3c appears to be involved in NF2 pathogenesis and deserves to be investigated as a prognostic marker for NF2 and target for treatment of NF2 patient tumors.
  • [MeSH-minor] Adult. Cell Line, Transformed. Cell Proliferation. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Humans. Immunoprecipitation. Meningioma / metabolism. Meningioma / pathology. Models, Biological. Neurofibromatoses / metabolism. Protein Structure, Tertiary. Recombinant Proteins / genetics. Recombinant Proteins / metabolism. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16497727.001).
  • [ISSN] 0964-6906
  • [Journal-full-title] Human molecular genetics
  • [ISO-abbreviation] Hum. Mol. Genet.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / KO8NS001428; United States / NINDS NIH HHS / NS / R01NS037883
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Eukaryotic Initiation Factor-3; 0 / Neurofibromin 2; 0 / Recombinant Proteins
  •  go-up   go-down


93. Chan AW, Black P, Ojemann RG, Barker FG 2nd, Kooy HM, Lopes VV, McKenna MJ, Shrieve DC, Martuza RL, Loeffler JS: Stereotactic radiotherapy for vestibular schwannomas: favorable outcome with minimal toxicity. Neurosurgery; 2005 Jul;57(1):60-70; discussion 60-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiotherapy for vestibular schwannomas: favorable outcome with minimal toxicity.
  • OBJECTIVE: To determine the outcome and toxicity in patients with vestibular schwannomas treated with conventionally fractionated stereotactic radiotherapy (SRT) and to identify prognostic factors that are predictive of outcome.
  • METHODS: Between 1992 and 2001, 70 patients with vestibular schwannomas were treated with linear accelerator-based SRT in our institutions.
  • Eleven patients had neurofibromatosis Type II (NF2).
  • There was no difference in tumor control and cranial nerve function preservation rates seen in NF2 patients compared with non-NF2 patients.
  • [MeSH-major] Dose Fractionation. Neuroma, Acoustic / surgery. Radiosurgery / methods. Stereotaxic Techniques. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15987541.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. An JH, Seong J, Oh H, Kim W, Han KH, Paik YH: [Protein expression profiles in a rat cirrhotic model induced by thioacetamide]. Korean J Hepatol; 2006 Mar;12(1):93-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: The reactive oxygen species from thioacetamide (TAA) induces rat liver cirrhosis that resembles the human disease, and it can serve as a suitable animal model for studying human liver cirrhosis.
  • In contrast, the expression level of the proteins did not show a significant change at 9 weeks, but this increased to 3-fold at 30 weeks for carbonic anhydrase VII, ras related protein Rab 6, Annexin A2, neurofibromatosis type 2 and aldehyde dehydrogenase.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THIOACETAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16565610.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Proteins; 075T165X8M / Thioacetamide
  •  go-up   go-down


95. Beyer KS, Beauchamp RL, Lee MF, Gusella JF, Näär AM, Ramesh V: Mediator subunit MED28 (Magicin) is a repressor of smooth muscle cell differentiation. J Biol Chem; 2007 Nov 2;282(44):32152-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Magicin, a protein that we isolated earlier as an interactor of the neurofibromatosis 2 protein merlin, was independently identified as MED28, a subunit of the mammalian Mediator complex.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848560.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS24279; United States / NINDS NIH HHS / NS / NS45776
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytoskeletal Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / MED28 protein, human; 0 / Mediator Complex
  •  go-up   go-down


96. Xiao GH, Gallagher R, Shetler J, Skele K, Altomare DA, Pestell RG, Jhanwar S, Testa JR: The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol; 2005 Mar;25(6):2384-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression.
  • Inactivation of the NF2 tumor suppressor gene has been observed in certain benign and malignant tumors.
  • Recent studies have demonstrated that merlin, the product of the NF2 gene, is regulated by Rac/PAK signaling.
  • In this report, we show that adenovirus-mediated expression of merlin in NF2-deficient tumor cells inhibits cell proliferation and arrests cells at G1 phase, concomitant with decreased expression of cyclin D1, inhibition of CDK4 activity, and dephosphorylation of pRB.
  • RNA interference experiments showed that silencing of the endogenous NF2 gene results in upregulation of cyclin D1 and S-phase entry.
  • Furthermore, PAK1-stimulated cyclin D1 promoter activity was repressed by cotransfection of NF2, and PAK activity was inhibited by expression of merlin.
  • Interestingly, the S518A mutant form of merlin, which is refractory to phosphorylation by PAK, was more efficient than the wild-type protein in inhibiting cell cycle progression and in repressing cyclin D1 promoter activity.

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] J Biol Chem. 1999 Sep 3;274(36):25245-9 [10464245.001]
  • [Cites] J Med Genet. 2000 Dec;37(12):897-904 [11106352.001]
  • [Cites] Genes Dev. 2001 Apr 15;15(8):968-80 [11316791.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34728-37 [11457831.001]
  • [Cites] Dev Cell. 2001 Jul;1(1):63-72 [11703924.001]
  • [Cites] Hum Mol Genet. 2002 Jan 1;11(1):69-76 [11773000.001]
  • [Cites] J Biol Chem. 2002 Jan 11;277(2):883-6 [11719502.001]
  • [Cites] Mol Cell Biol. 2002 Feb;22(4):1150-7 [11809806.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10394-9 [11782491.001]
  • [Cites] Mol Cell Biol. 2002 Sep;22(17):6023-33 [12167697.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Sep 6;296(5):1295-302 [12207915.001]
  • [Cites] Genes Dev. 2003 May 1;17(9):1090-100 [12695331.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):841-9 [14580336.001]
  • [Cites] Cell Cycle. 2004 Jan;3(1):71-4 [14657670.001]
  • [Cites] J Biol Chem. 2004 Jan 9;279(2):1422-8 [14530270.001]
  • [Cites] Cancer J. 2004 Jan-Feb;10(1):20-6 [15000491.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(17):7598-611 [15314168.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):2066-76 [8114738.001]
  • [Cites] J Biol Chem. 1994 Sep 23;269(38):23387-90 [8089100.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1227-31 [7882313.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2270-4 [7757975.001]
  • [Cites] J Biol Chem. 1995 Oct 6;270(40):23589-97 [7559524.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10854-8 [7479897.001]
  • [Cites] Mol Cell Biol. 1997 Mar;17(3):1324-35 [9032259.001]
  • [Cites] Oncogene. 1997 Nov 13;15(20):2505-9 [9395247.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2509-14 [9482916.001]
  • [Cites] Genes Dev. 1998 Apr 15;12(8):1121-33 [9553042.001]
  • [Cites] J Cell Biol. 1998 Jun 29;141(7):1589-99 [9647651.001]
  • [Cites] Int J Cancer. 1998 Aug 12;77(4):554-60 [9679758.001]
  • [Cites] Oncogene. 1998 Oct 29;17(17):2195-209 [9811451.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] J Neurosurg. 1999 Jul;91(1):85-92 [10389885.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Mar;24(3):238-42 [10451704.001]
  • [Cites] Cell. 2000 Oct 13;103(2):227-38 [11057896.001]
  • (PMID = 15743831.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA075503; United States / NCI NIH HHS / CA / R01 CA093596; United States / NCI NIH HHS / CA / R01 CA045745; United States / NCI NIH HHS / CA / R29 CA070896; United States / NCI NIH HHS / CA / R01 CA070896; United States / PHS HHS / / T32-16850; United States / NCI NIH HHS / CA / CA-45745; United States / NCI NIH HHS / CA / CA-75503; United States / NCI NIH HHS / CA / CA-93596; United States / NCI NIH HHS / CA / R01 CA086072; United States / NCI NIH HHS / CA / CA-86072; United States / NCI NIH HHS / CA / P30 CA006927; United States / NCI NIH HHS / CA / CA-70896; United States / NCI NIH HHS / CA / CA-06927
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurofibromin 2; 0 / RNA, Small Interfering; 136601-57-5 / Cyclin D1; EC 2.7.11.1 / PAK1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / p21-Activated Kinases
  • [Other-IDs] NLM/ PMC1061616
  •  go-up   go-down


97. Ikeda T, Hashimoto S, Fukushige S, Ohmori H, Horii A: Comparative genomic hybridization and mutation analyses of sporadic schwannomas. J Neurooncol; 2005 May;72(3):225-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Schwannomas of the vestibular nerve are the striking characteristics of neurofibromatosis type 2 (NF2), an autosomal dominant hereditary disease.
  • The NF2 gene on 22q12 has been isolated as the gene responsible for NF2.
  • Previous studies have reported that 60% of sporadic schwannomas showed inactivation of the NF2 gene, but genetic alterations of remaining 40% tumors remain elusive.
  • Loss of chromosome 22q, including the NF2 locus, was the only notable abnormality (5/17, 29%).
  • Further, we performed fluorescence in situ hybridization analysis with a genomic BAC clone harboring the NF2 gene and found that the 5 tumors with loss detected by CGH as well as three cases without such a detectable loss by CGH, or a total, 8/17 (47%), showed loss of the NF2 locus.
  • Mutation search by PCR-SSCP followed by direct sequencing revealed that 71% (12/17) of the tumors had one or two mutations in the NF2 gene.
  • Our analyses disclosed that 14 (82%) of 17 tumors had structural alteration of NF2; among these 14 cases, 9 (64%) had two inactivating mutations in the NF2 gene, either a somatic mutation in one allele coupled with loss of the other allele or two independent somatic mutations.
  • Our present results suggested that (i) most of the sporadic schwannomas have two-hit mutations in the NF2 gene, and (ii) NF2 is the only major causative gene in the genesis of schwannomas that is activated or inactivated by copy number alterations.
  • [MeSH-minor] Adult. Aged. DNA Mutational Analysis. DNA Primers. Female. Genes, Neurofibromatosis 2. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Nucleic Acid Hybridization. Polymorphism, Single-Stranded Conformational. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Q J Med. 1992 Aug;84(304):603-18 [1484939.001]
  • [Cites] J Med Genet. 2003 Nov;40(11):802-6 [14627667.001]
  • [Cites] Genomics. 1989 Nov;5(4):874-9 [2687159.001]
  • [Cites] Eur J Surg Oncol. 1997 Aug;23(4):298-303 [9315056.001]
  • [Cites] Hum Mol Genet. 1994 Mar;3(3):413-9 [8012353.001]
  • [Cites] Nature. 1986 Aug 14-20;322(6080):644-7 [3092103.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Jul;19(3):161-9 [9218997.001]
  • [Cites] Hum Genet. 1986 Dec;74(4):346-52 [3793097.001]
  • [Cites] J Med Genet. 1992 Dec;29(12 ):841-6 [1479598.001]
  • [Cites] Oncogene. 1993 Sep;8(9):2399-405 [8395678.001]
  • [Cites] Hum Mol Genet. 1998 Dec;7(13):2095-101 [9817927.001]
  • [Cites] Am J Hum Genet. 1996 Aug;59(2):331-42 [8755919.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • [Cites] Br J Cancer. 2000 Jun;82(11):1801-7 [10839294.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Feb;130(2):216-20 [14967754.001]
  • [Cites] Hum Genet. 1999 May;104(5):418-24 [10394935.001]
  • [Cites] Nature. 1987 Sep 17-23;329(6136):246-8 [2888021.001]
  • [Cites] Cell. 1993 Mar 12;72(5):791-800 [8453669.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5601-6 [14654541.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(10):1099-104; discussion 1104-5 [11129530.001]
  • [Cites] Mol Cell Biol. 1986 Sep;6(9):3156-65 [3785225.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Sep;17(1):45-55 [8889506.001]
  • [Cites] Oncol Rep. 2004 Nov;12(5):1099-103 [15492799.001]
  • [Cites] Arch Ophthalmol. 1989 Apr;107(4):541-4 [2705922.001]
  • [Cites] Chromosoma. 1987;95(6):375-86 [3677921.001]
  • [Cites] Neurology. 2003 Jun 24;60(12):1968-74 [12821741.001]
  • (PMID = 15937644.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Neoplasm
  •  go-up   go-down


98. Seki Y, Samejima N, Komatsuzaki A: Auditory brainstem implants: current state and future directions with special reference to the subtonsillar approach for implantation. Acta Neurochir Suppl; 2007;97(Pt 2):431-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The CI restores hearing by stimulating the cochlear nerve in the cochlea in patients whose deafness has been caused by inner ear disease; the ABI restores hearing by stimulating the cochlear nucleus of the brainstem in patients who are deaf because of bilateral cochlear nerve dysfunction.
  • Up to now, about 500 patients worldwide have undergone ABI and had their hearing restored, most of whom suffer from neurofibromatosis type 2.
  • [MeSH-minor] Cochlear Implantation / methods. Humans. Neurofibromatosis 2 / complications. Neurofibromatosis 2 / surgery. Physical Stimulation / methods

  • MedlinePlus Health Information. consumer health - Hearing Disorders and Deafness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17691332.001).
  • [ISSN] 0065-1419
  • [Journal-full-title] Acta neurochirurgica. Supplement
  • [ISO-abbreviation] Acta Neurochir. Suppl.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 20
  •  go-up   go-down


99. Gao X, Zhang R, Mao Y, Wang Y: Childhood and juvenile meningiomas. Childs Nerv Syst; 2009 Dec;25(12):1571-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Fifty-four meningioma cases below the age of 18 have been treated in Huashan Hospital in the last 15 years (from 1993 to 2008), their sex and age distribution, clinical manifestation, radiological finding, pathological subtype, treatment, and prognosis are retrospectively analyzed, and the results are compared with those reported in the literature.
  • Five patients in this series were associated with neurofibromatosis-2.
  • The most common radiological finding was homogeneous enhancement with contrast.
  • All of these patients were surgically treated; resection both in Simpson grades I and II could be achieved in 39 out of 54 patients.
  • Fibroblastic meningiomas were the most common pathological subtype, and malignant and atypical meningiomas (both of grades II and III according to WHO classification) accounted for 18.5% of the whole series.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / surgery. Meningioma / diagnosis. Meningioma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1998 May;38(1):41-9 [9540056.001]
  • [Cites] Br J Neurosurg. 1997 Dec;11(6):501-7 [11013621.001]
  • [Cites] Am J Epidemiol. 2007 Mar 1;165(5):477-85 [17182979.001]
  • [Cites] J Child Neurol. 2006 Jan;21(1):31-6 [16551450.001]
  • [Cites] Surg Neurol. 1984 Apr;21(4):319-22 [6701761.001]
  • [Cites] Pediatr Neurosurg. 2005 Jan-Feb;41(1):1-7 [15886506.001]
  • [Cites] Childs Nerv Syst. 1987;3(5):271-3 [3427568.001]
  • [Cites] J Clin Neurosci. 2004 Sep;11(7):715-8 [15337131.001]
  • [Cites] Pediatr Neurosurg. 1992;18(1):16-23 [1419837.001]
  • [Cites] Childs Nerv Syst. 1989 Apr;5(2):83-6 [2736555.001]
  • [Cites] J Neurooncol. 2000;46(3):205-13 [10902852.001]
  • [Cites] Mol Cell Endocrinol. 2006 Jul 25;254-255:1-7 [16824680.001]
  • [Cites] Int J Cancer. 1995 Aug 22;64(4):223-8 [7657383.001]
  • [Cites] Acta Neurochir (Wien). 1993;125(1-4):34-40 [8122553.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):994-1003 [11589430.001]
  • [Cites] J Neurosurg. 2004 Feb;100(2 Suppl Pediatrics):179-82 [14758946.001]
  • [Cites] J Neurooncol. 2006 Mar;77(1):73-7 [16292489.001]
  • [Cites] Pediatr Neurosurg. 2008;44(1):43-8 [18097190.001]
  • [Cites] Cancer. 1976 Jun;37(6):2709-12 [949689.001]
  • [Cites] Crit Rev Neurosurg. 1999 May 25;9(3):180-188 [10369973.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Childs Nerv Syst. 2007 Feb;23(2):157-62 [16953459.001]
  • [Cites] Childs Nerv Syst. 2000 Jul;16(7):406-16 [10958549.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(5):485-93; discussion 493-4 [8800322.001]
  • [Cites] J Clin Neurosci. 2007 Aug;14(8):747-53 [17499508.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):197-205 [8858525.001]
  • [Cites] Childs Nerv Syst. 2001 Nov;17 (11):656-62 [11734983.001]
  • [Cites] Childs Brain. 1980;7(1):43-56 [7428495.001]
  • [Cites] Pathol Res Pract. 2008;204(5):305-14 [18374497.001]
  • [Cites] Neurosurgery. 1992 Aug;31(2):179-85 [1513424.001]
  • [Cites] Surg Neurol. 1987 Jan;27(1):64-8 [3787443.001]
  • [Cites] J Neurosurg. 1996 Dec;85(6):1095-101 [8929501.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):140-5 [9490273.001]
  • [Cites] Lancet. 2004 May 8;363(9420):1535-43 [15135603.001]
  • [Cites] Int J Surg Pathol. 2007 Apr;15(2):110-5 [17478763.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):441-52 [9888154.001]
  • [Cites] Pathol Res Pract. 2000;196(7):483-8 [10926326.001]
  • [Cites] Neuropathology. 2007 Oct;27(5):407-12 [18018472.001]
  • [Cites] Surg Neurol. 2003 Oct;60(4):298-305; discussion 305 [14505844.001]
  • [Cites] Pediatr Neurosurg. 2008;44(2):112-7 [18230924.001]
  • [Cites] Childs Nerv Syst. 1996 Oct;12(10):582-8; discussion 589 [8934017.001]
  • [Cites] J Neurosurg. 1982 Mar;56(3):317-22 [7057228.001]
  • [Cites] Surg Neurol. 1998 Feb;49(2):136-40; discussion 140-1 [9457262.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Mar-Apr;24(3):199-204 [11990306.001]
  • [Cites] J Neurosurg. 1994 Mar;80(3):447-53 [8113857.001]
  • [Cites] Neuroradiology. 1999 Jul;41(7):512-6 [10450846.001]
  • [Cites] Surg Neurol. 1996 Apr;45(4):328-35 [8607080.001]
  • (PMID = 19641924.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


100. Larsson J, Ohishi M, Garrison B, Aspling M, Janzen V, Adams GB, Curto M, McClatchey AI, Schipani E, Scadden DT: Nf2/merlin regulates hematopoietic stem cell behavior by altering microenvironmental architecture. Cell Stem Cell; 2008 Aug 7;3(2):221-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nf2/merlin regulates hematopoietic stem cell behavior by altering microenvironmental architecture.
  • We assessed whether the tumor suppressor and mediator of cell contact inhibition Nf2/merlin plays a role in governing the hematopoietic stem cell pool by stem cell-autonomous or niche-determined processes.
  • Hematopoietic stem cells in Nf2-deficient mice were increased in number and demonstrated a marked shift in location to the circulation.
  • Nf2/merlin is critical for maintaining normal structure and function of the hematopoietic stem cell niche.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18682243.001).
  • [ISSN] 1875-9777
  • [Journal-full-title] Cell stem cell
  • [ISO-abbreviation] Cell Stem Cell
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL044851; United States / NCI NIH HHS / CA / CA113733; United States / NHLBI NIH HHS / HL / HL081030; United States / NHLBI NIH HHS / HL / HL44851; United States / NHLBI NIH HHS / HL / U54 HL081030
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurofibromin 2; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ NIHMS65568; NLM/ PMC4197168
  •  go-up   go-down






Advertisement